Sound credit scores and financial decisions despite cognitive aging
暂无分享,去创建一个
Rameen Beroukhim | William C Hahn | Pratiti Bandopadhayay | Andrew L Kung | W. Hahn | R. Beroukhim | A. Schinzel | J. Bradner | D. Livingston | R. Drapkin | A. Kung | C. Bowman-Colin | Lisa Zaval | P. Bandopadhayay | Joyce F. Liu | Y. Zwang | Huiying Piao | Ronny Drapkin | Anna C Schinzel | James E Bradner | Yaara Zwang | H. Piao | Joyce F Liu | David M Livingston | Maria Giuseppina Baratta | Christian Bowman-Colin | Jennifer Kutt | Jennifer Curtis | Laura C Wong | M. Baratta | J. Curtis | A. Z. Enkavi | J. Kutt | Laurie Wong | Yaara Zwang | Christian Bowman-Colin | Eric J. Johnson | Ye Li | Jie Gao | Elke U. Weber
[1] Qiang Zhang,et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. , 2014, Cancer cell.
[2] Zhaohui S. Qin,et al. Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.
[3] Paola Chiarugi,et al. Microenvironment and tumor cell plasticity: an easy way out. , 2013, Cancer letters.
[4] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[5] R. Berkowitz,et al. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. , 2005, Gynecologic oncology.
[6] R. Bast,et al. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. , 2012, Endocrinology.
[7] W. Hahn,et al. Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer , 2013, Clinical Cancer Research.
[8] Caroline Dive,et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer , 2010, Cancer biology & therapy.
[9] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[10] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[11] H. Johnsen,et al. Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers , 2011, PloS one.
[12] W. Ou,et al. Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. , 2013, The international journal of biochemistry & cell biology.
[13] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[14] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[15] H. Varmus,et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.
[16] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[17] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[18] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[19] David D. L. Bowtell,et al. The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.
[20] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[21] M. Bergo,et al. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors , 2012, Oncogene.
[22] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[23] Young Tae Kim,et al. NM23 as a prognostic biomarker in ovarian serous carcinoma , 2008, Modern Pathology.
[24] L. Leng,et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. , 2002, Cancer research.
[25] D. Chan,et al. Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications , 2012, BMC Cancer.
[26] K. Stegmaier,et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.
[27] Shwu‐Yuan Wu,et al. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.
[28] E. Lundberg,et al. Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.
[29] Michael Q. Zhang,et al. Identification of Tumor Suppressors and Oncogenes from Genomic and Epigenetic Features in Ovarian Cancer , 2011, PloS one.
[30] H. Husseinzadeh,et al. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. , 2014, Gynecologic oncology.
[31] Birgit Schoeberl,et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. , 2010, Cancer cell.
[32] R. Beroukhim,et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.
[33] W. Weichert,et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma , 2004, British Journal of Cancer.
[34] D. Aoki,et al. Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. , 2013, Biomedical reports.
[35] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[36] G. Ganji,et al. BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.
[37] Q. Ji,et al. Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins , 2014, Pathology & Oncology Research.